RECRUITING

Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to develop an educational aid about hormone replacement therapy that physicians can share with patients as part of their pre-surgical counseling for a risk-reducing salpingo-oophorectomy (RRSO).

Official Title

Patient Centered Education About Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy: a Pilot Randomized Controlled Trial

Quick Facts

Study Start:2025-08-01
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06972719

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:19 Years to 50 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * BRCA1 or BRCA2 germline mutation
  2. * scheduled for a risk-reducing salpingo-oophorectomy (RRSO) by Duke Gynecologic Oncologist
  3. * premenopausal
  1. * personal history of cancer
  2. * postmenopausal
  3. * \>50 years old
  4. * unable to provide informed consent in English

Contacts and Locations

Study Contact

Amelia Scott
CONTACT
(919) 613-4584
amelia.lorenzo@duke.edu

Principal Investigator

Laura Havrilesky
PRINCIPAL_INVESTIGATOR
Duke University

Study Locations (Sites)

Duke University Health System
Durham, North Carolina, 27710
United States

Collaborators and Investigators

Sponsor: Duke University

  • Laura Havrilesky, PRINCIPAL_INVESTIGATOR, Duke University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-08-01
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2025-08-01
Study Completion Date2026-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • BRCA1 Mutation
  • BRCA2 Mutation